Results 171 to 180 of about 13,380 (189)

Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy

American Journal of Kidney Diseases, 2018
Fadi Fakhouri, Stéphane Decramer, Eric Daugas   +2 more
exaly  

Eculizumab

Reactions Weekly, 2019
openaire   +2 more sources

Current Evidence on the Discontinuation of Eculizumab in Patients With Atypical Haemolytic Uraemic Syndrome.

CKJ: Clinical Kidney Journal, 2017
Nils Heyne, Tina Dutt, Christoph Gasteyger   +2 more
exaly  

Eculizumab in Atypical Hemolytic Uremic Syndrome: Strategies Toward Restrictive Use

Pediatric Nephrology, 2019
Jack F M Wetzels, Caroline Duineveld
exaly  

Eculizumab Therapy in Children With Severe Hematopoietic Stem Cell Transplantation–Associated Thrombotic Microangiopathy

Biology of Blood and Marrow Transplantation, 2014
Lily Lu, Fred G Pluthero, Tsuyoshi Fukuda   +2 more
exaly  

Monitoring of Complement Activation Biomarkers and Eculizumab in Complement-Mediated Renal Disorders.

Clinical and Experimental Immunology, 2017
Rolf Weimer, B Hoppe, M Bommer
exaly  

Therapeutic Drug Monitoring of Eculizumab: Rationale for an Individualized Dosing Schedule

MAbs, 2015
Hervé Watier, Guillaume Brachet, Christelle Barbet   +2 more
exaly  

Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis

Muscle and Nerve, 2019
Maurizio Inghilleri, John Vissing, Josef Bednařík   +2 more
exaly  

A Randomized, Double-Blind, Single-Dose, Three-Arm, Parallel Group Study to Determine Pharmacokinetic Similarity of ABP 959 and Eculizumab (Soliris®) in Healthy Male Subjects

European Journal of Haematology, 2020
Vladimir Hanes, David Chien, Vincent Chow   +2 more
exaly  

RECOMBINANT GLYCOSYLATED ECULIZUMAB AND ECULIZUMAB VARIANTS

2017
ANDRIEN BRUCE, HUNTER JEFFREY, MALANSON HUNTER   +2 more
openaire   +5 more sources